Need for Prophylactic Treatment in Adult Haemophilia A Patients

被引:5
|
作者
Siegmund, Berthold [1 ]
Richter, Heinrich [1 ]
Pollmann, Hartmut [1 ]
机构
[1] Inst Thrombophilie & Hamostaseol, D-48143 Munster, Germany
关键词
Haemophilia A; On-demand therapy; Continuous prophylaxis; FACTOR-VIII; EXPERIENCE; CHILDREN; OUTCOMES; THERAPY; DISEASE; BOYS;
D O I
10.1159/000225965
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Methods: A single centre study including 52 German patients aged 16 years with severe haemophilia A was performed to compare the amount of clotting factor and outcome between on-demand therapy (26 patients) and continuous prophylaxis (26 patients) over 1 year. Results: Prophylaxis reduced the number of bleeds significantly. Compared to on-demand treatment (20.5 +/- 3.0 bleeds/year/patient), under prophylaxis 7.8 +/- 1.3 bleeds/year/patient were observed. Joint bleeds were reduced from 12.2 +/- 1.5 to 4.7 +/- 1.0/year/patient. In the on-demand group 38% of the patients suffered from more than 2 bleeds/month, whereas in the prophylaxis group no patient was found with more than 2 bleeds/month. Mean annual factor VIII (FVIII) consumption increased from 767 +/- 110 IU/kg body weight under on-demand treatment to 2,841 +/- 341 IU/kg body weight under continuous prophylaxis, displaying a nearly fourfold increase in FVIII consumption. Furthermore, prophylaxis implies a more than four-fold increase in treatment days which escalated from a mean weekly injection rate of 0.56 +/- 0.08 FVIII injections/week when bleeds were treated on demand to 2.52 +/- 0.30 FVIII injections/week during prophylaxis. Conclusion: Even though the results reflect a benefit also for prophylactically treated patients regarding their bleeding frequency, one has to take into account a substantial increase of the costs for coagulation concentrates when all patients with severe haemophilia A switch to continuous prophylaxis.
引用
收藏
页码:283 / 288
页数:6
相关论文
共 50 条
  • [21] Prophylactic treatment with recombinant activated factor VII in paediatric patients with haemophilia A and inhibitors
    Cermelj, M. A.
    Ferro, A. M.
    Ouvina, S. M.
    Pollola, J. A.
    Paoloski, G. B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 694 - 695
  • [22] DISEASE BURDEN ANALYSIS OF PROPHYLACTIC TREATMENT VERSU3 ON-DEMAND TREATMENT FOR ADULT PATIENTS WITH MODERATE-TO-SEIERE HAEMOPHILIA A IN CHINA
    Tan, B.
    Lin, A.
    Xuan, J.
    Han, L.
    Hu, N.
    Bai, L.
    Sun, J.
    Hu, S.
    VALUE IN HEALTH, 2022, 25 (12) : S181 - S181
  • [23] Prophylactic Treatment of Severe Haemophilia a Patients with Inhibitors to FVIII with Peglip-FVIII
    Tuddenham, Edward
    Wolf-Garraway, Richard
    Ling, Gavin
    BLOOD, 2022, 140 : 5617 - 5618
  • [24] Quality of life assessment and pharmacokinetic study in haemophilia A patients undergoing prophylactic treatment
    Kotsiou, N.
    Gavriilaki, E.
    Chissan, S.
    Ntova, Z.
    Moka, E.
    Aivazidou, S.
    Katsetsiadis, A.
    Kalmoukos, P.
    Vakalopoulou, S.
    HAEMOPHILIA, 2024, 30 : 109 - 110
  • [25] Predictors of treatment difficulties and satisfaction with haemophilia therapy in adult patients
    Remor, E.
    HAEMOPHILIA, 2011, 17 (05) : E901 - E905
  • [26] Personalizing prophylactic treatment in adult patients with severe hemophilia A
    Klamroth, R.
    Lissitchkov, T.
    Walter, O.
    Knaub, S.
    Bichler, J.
    Tiede, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 : 42 - 42
  • [27] Improved arthropathy scores after use of Extended Half-Life (EHL) products in prophylactic treatment of adult patients with Haemophilia A & B
    Christidi, Styliani-Despoina
    Thevaeos, George
    Zannou, Anna
    Vlahopoulou, Dimitra
    Veziris, George
    Gavalaki, Maria
    Kourampa, Anna
    HAEMOPHILIA, 2023, 29 : 38 - 39
  • [28] IMPROVED ARTHROPATHY SCORES AFTER USE OF EXTENDED HALF LIFE (EHL) PRODUCTS IN PROPHYLACTIC TREATMENT OF ADULT PATIENTS WITH SEVERE HAEMOPHILIA A AND B
    Kouramba, A.
    Thivaios, G.
    George, V.
    Elefterios, K.
    Zygogiannis, K.
    Katsarou, O.
    HAEMOPHILIA, 2020, 26 : 53 - 53
  • [29] Barriers to prophylactic treatment among patients with haemophilia A in Shandong Province, China: a qualitative study
    Ziyu Liu
    Junchao Feng
    Yunhai Fang
    Yan Cheng
    Shunping Li
    Orphanet Journal of Rare Diseases, 18
  • [30] Nonfactor Therapies: New Approaches to Prophylactic Treatment of Haemophilia
    Chowdary, Pratima
    HAMOSTASEOLOGIE, 2021, 41 (04): : 247 - 256